Compare CEPV & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPV | ZNTL |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.8M | 289.0M |
| IPO Year | N/A | 2020 |
| Metric | CEPV | ZNTL |
|---|---|---|
| Price | $10.30 | $3.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 42.7K | ★ 952.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.06 | $1.13 |
| 52 Week High | $10.35 | $6.95 |
| Indicator | CEPV | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 41.94 |
| Support Level | $10.19 | $1.34 |
| Resistance Level | $10.31 | $4.38 |
| Average True Range (ATR) | 0.02 | 0.29 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 84.62 | 18.13 |
Cantor Equity Partners V Inc is a blank check company.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.